A comparative study of QT prolongation with serotonin reuptake inhibitors
- 3 August 2017
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 234 (20) , 3075-3081
Abstract
QT interval prolongations were described with citalopram and escitalopram. However, the effects of the other serotonin reuptake inhibitors (SRIs) remained discussed. In order to identify a putative signal with other SRIs, the present study investigates the reports of QT interval prolongation with SRIs in two pharmacovigilance databases (PVDB).Keywords
This publication has 23 references indexed in Scilit:
- Outcomes of Citalopram Dosage Risk Mitigation in a Veteran PopulationAmerican Journal of Psychiatry, 2016
- Use of selective serotonin re‐uptake inhibitors and the heart rate corrected QT interval in a real‐life setting: the population‐based Rotterdam StudyBritish Journal of Clinical Pharmacology, 2015
- QT interval and antidepressant use: a cross sectional study of electronic health recordsBMJ, 2013
- Antidepressant Use and Risk of Out-of-Hospital Cardiac Arrest: A Nationwide Case–Time–Control StudyClinical Pharmacology & Therapeutics, 2012
- Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance databaseBritish Journal of Clinical Pharmacology, 2011
- Antidepressants and the risk of sudden cardiac death and ventricular arrhythmiaPharmacoepidemiology and Drug Safety, 2011
- QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in FranceFundamental & Clinical Pharmacology, 2010
- Drug‐induced torsades de pointes: a review of the Swedish pharmacovigilance databasePharmacoepidemiology and Drug Safety, 2008
- The application of knowledge discovery in databases to post‐marketing drug safety: example of the WHO databaseFundamental & Clinical Pharmacology, 2008
- Drug induced QT prolongation and torsades de pointesHeart, 2003